News

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia
Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition of Rallybio’s (NASDAQ: RLYB) full interest in their joint ...
Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?
Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.
GEN - Genetic Engineering and Biotechnology News5d
Democratizing Artificial Intelligence in Pre-Clinical Drug Discovery
While AI-driven approaches tout increased speed and lower costs, commercial interests compromise scientific collaboration.
Cantech Letter5d
Doctors Are Being Outpaced by AI-Powered Algorithms — Here’s What It Means for Investors
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 7, 2025 /CNW/ — USA News Group News Commentary – This week in Geneva, the World Health Organization ...
Doctors Are Being Outpaced By AI-Powered Algorithms - Here's What It Means For Investors - Financial News Media
As a physician-centric, AI-powered organization, Astrana sees the acquisition as a way to scale its proactive, high-quality care model using proprietary tech and data infrastructure. The company ...
USA News Group: Doctors Are Being Outpaced by AI-Powered Algorithms -- Here's What It Means for Investors
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 7, 2025 /PRNewswire/ -- USA News Group News Commentary - This week in Geneva, the World Health ...